^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:conteltinib (SY-707) (ALK inhibitor, Multi-tyrosine kinase inhibitor, IGF-1R inhibitor, FAK inhibitor, Pyk2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

    Excerpt:
    ...Patients must be diagnosed with ALK-positive advanced NSCLC....
    Trial ID:
    NCT02695550
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Med
    Title:

    Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

    Published date:
    11/23/2022
    Excerpt:
    In this study, conteltinib showed manageable safety profile, favorable PK properties, and anti-tumor activity in advanced ALK-positive NSCLC patients.
    DOI:
    https://doi.org/10.1186/s12916-022-02646-0